ABSTRACT
A woman in her 70s developed deep vein thromboembolism(DVT)and pulmonary embolism(PE)during chemotherapy for advanced transverse colon cancer. After the first treatment with heparin and warfarin, the anticoagulant was changed to edoxaban to reduce the risk of bleeding. She continued receiving chemotherapy for 4 years. We recommend edoxaban as the first choice of anticoagulant for patients with DVT and PE requiring chemotherapy with fluoropyrimidine-based antineoplastic agents.
Subject(s)
Anticoagulants/adverse effects , Colonic Neoplasms , Fluorouracil/therapeutic use , Pulmonary Embolism , Pyridines/adverse effects , Thiazoles/adverse effects , Thromboembolism , Venous Thromboembolism , Aged , Colonic Neoplasms/drug therapy , Humans , Pulmonary Embolism/chemically induced , Venous Thromboembolism/chemically inducedABSTRACT
A 63-year-old man was admitted to our department following a secondary medical examination. Blood tests showed high levels of liver enzymes, IgG, IgG4, and antinuclear antibody. Computed tomography showed tumors in the bilateral lower lobes of the lungs and pleural thickening. After pleural and liver biopsy procedures, he was conclusively diagnosed with IgG4-related lung pseudotumor and pleural inflammation with autoimmune hepatitis. We started treatment with prednisolone 40 mg/day, and chest radiograph and blood tests showed signs of improvement. This was a rare case that suggested an association between IgG4-related disease and autoimmune hepatitis.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Hepatitis, Autoimmune/drug therapy , Inflammation/drug therapy , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Prednisolone/therapeutic use , Biopsy , Humans , Immunoglobulin G/blood , Lung/physiopathology , Lung Neoplasms/diagnosis , Male , Middle Aged , Pleura/physiopathology , Treatment OutcomeABSTRACT
A 72-year-old woman having abdominal pain and high fever was diagnosed with KRAS wild-type sigmoid colon cancer, invading the urinary bladder and uterus with a pelvic abscess. Considering the difficulty of curative resection, we first performed sigmoid colostomy and abscess drainage. Remarkable tumor regression was indicated by CT and colonoscopy after 1 course of FOLFIRI and 5 courses of FOLFIRI+panitumumab. Following an additional 2 courses of panitumumab, sigmoidectomy and partialcystectomy were performed. Six courses of FOLFIRI+panitumumab were administered postoperatively and no recurrence has been observed for 7 months. FOLFIRI+panitumumab may be an effective preoperative chemotherapy for patients with KRAS wild-type locally advanced colon cancer.